MiRNA-205-5p Promotes Development of Hepatocellular Carcinoma Via Targeting DLC1

Abstract

Abstract Purpose: Researching biomarkers is of great significance for immunotherapy of hepatocellular carcinoma (HCC). The purpose is to research the level and specific function of miR-205-5p in HCC and analyzed related genes, hoping to lay a theoretical basis for HCC treatment. Methods: The HCC tissues and controls were obtained from hepatocellular carcinoma patients. Human liver immortalized cells (THLE2) and four HCC lines (huh-7, HepG2, HCCLM3, SK-Hep-1) were used in vitro. MiR-205-5p inhibitor, mimic, sh-CD302 Molecule (sh-DCL1) and their corresponding controls were transfected. Starbase and dual-luciferase reporter assay were undertaken for predicting and verifying the binding of miR-205-5p and DLC1. CCK8, EdU, flow cytometry assay was processed to detect cell viability, proliferation and apoptosis. Wound healing and transwell experiment were undertaken to monitor metastasis capability. Results: There was higher level of miR-205-5p in hepatocellular carcinoma samples. Knockdown of miR-205-5p inhibited the proliferation and improved apoptosis of huh-7 and HepG2 cells. Moreover, miR-205-5p-inhibitor decreased the migration and invasion of HCC cells. MiR-205-5p targeted and negatively adjusted DLC1. Interestingly, sh-DLC1 rescued the influence of miR-205-5p-inhibitor. Conclusion: MiRNA-205-5p promoted the occurrence and development of HCC via targeting DLC1, which was researched as a potential target for HCC therapy.